Three-Dimensional Bioprinting of Human Organs and Tissues: Bioethical and Medico-Legal Implications Examined through a Scoping Review.

bioethics bioprinting precision medicine tissue engineering

Journal

Bioengineering (Basel, Switzerland)
ISSN: 2306-5354
Titre abrégé: Bioengineering (Basel)
Pays: Switzerland
ID NLM: 101676056

Informations de publication

Date de publication:
07 Sep 2023
Historique:
received: 13 08 2023
revised: 29 08 2023
accepted: 05 09 2023
medline: 28 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Three-dimensional bioprinting is a rapidly evolving technology that holds the promise of addressing the increasing demand for organs, tissues, and personalized medicine. By employing computer-aided design and manufacturing processes, 3D bioprinting allows for the precise deposition of living cells, biomaterials, and biochemicals to create functional human tissues and organs. The potential applications of this technology are vast, including drug testing and development, disease modeling, regenerative medicine, and ultimately, organ transplantation. However, as with any groundbreaking technology, 3D bioprinting presents several ethical, legal, and regulatory concerns that warrant careful consideration. As the technology progresses towards clinical applications, it is essential to address these challenges and establish appropriate frameworks to guide the responsible development of 3D bioprinting. This article, utilizing the Arksey and O'Malley scoping review model, is designed to scrutinize the bioethical implications, legal and regulatory challenges, and medico-legal issues that are intertwined with this rapidly evolving technology.

Identifiants

pubmed: 37760154
pii: bioengineering10091052
doi: 10.3390/bioengineering10091052
pmc: PMC10525297
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Biomolecules. 2022 Jan 12;12(1):
pubmed: 35053272
Tissue Eng Part B Rev. 2008 Dec;14(4):367-75
pubmed: 18834330
Front Bioeng Biotechnol. 2020 Oct 08;8:924
pubmed: 33154961
Syst Synth Biol. 2009 Dec;3(1-4):47-54
pubmed: 19816799
Acta Biomater. 2020 May;108:87-96
pubmed: 32268237
Clin Ter. 2023 Jan-Feb;174(1):80-84
pubmed: 36655649
Xenotransplantation. 2016 Jul;23(4):258-68
pubmed: 27388035
Endocr Rev. 2009 May;30(3):204-13
pubmed: 19366754
Sci Eng Ethics. 2018 Feb;24(1):73-91
pubmed: 28185142
BMC Med. 2022 Dec 27;20(1):499
pubmed: 36575403
Sci Eng Ethics. 2018 Apr;24(2):335-348
pubmed: 28660387
Front Med Technol. 2021 Jan 28;2:607648
pubmed: 35047890
Ann Surg. 2017 Jul;266(1):48-58
pubmed: 28594678
Int J Bioprint. 2020 Apr 28;6(3):272
pubmed: 33088986
Soc Sci Med. 2006 Nov;63(9):2277-88
pubmed: 16905231
Sci Eng Ethics. 2016 Oct;22(5):1285-1297
pubmed: 26387090
Acta Biomater. 2020 May;108:97-110
pubmed: 32165193
Trends Biotechnol. 2023 Jan;41(1):6-9
pubmed: 36117024
Surgeon. 2004 Apr;2(2):70-8
pubmed: 15568431
Biomed Mater. 2020 Dec 16;16(1):015007
pubmed: 32674078
ACS Omega. 2020 Aug 12;5(33):21015-21023
pubmed: 32875238
Regen Med. 2023 Aug;18(8):659-674
pubmed: 37403962
Front Bioeng Biotechnol. 2023 Apr 07;11:1108396
pubmed: 37091338
J Med Ethics. 2017 Sep;43(9):618-624
pubmed: 28320774
Biomater Sci. 2021 Jun 15;9(12):4278-4288
pubmed: 33165491

Auteurs

Giovanna Ricci (G)

Section of Legal Medicine, School of Law, University of Camerino, IT-62032 Macerata, Italy.

Filippo Gibelli (F)

Section of Legal Medicine, School of Law, University of Camerino, IT-62032 Macerata, Italy.

Ascanio Sirignano (A)

Section of Legal Medicine, School of Law, University of Camerino, IT-62032 Macerata, Italy.

Classifications MeSH